Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 3, 2015
Pharmacy Choice - News - Generic Drugs - July 3, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 51     Next >>     Go To Page:

7/3/15 - Big Pharma looks to long term in China [China Daily: Europe Weekly]
While the situation provides opportunities for big pharma companies to expand their markets in China, they are also hoping that offshoring research and development to China may contribute to reconfiguring their R&D models with its weak record of producing new drugs. Drawing on interviews with pharma R&D centers in Shanghai, patent analyses and indu
7/3/15 - Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case [FARS News Agency]
According to an Order issued in the U.S. District Court, Southern District of West Virginia on June 26th, the Court rejected the Plaintiff's assertion that one manufacturer can be held liable for injuries stemming from another manufacturer's product. Because of FDA regulations governing generic drug labels, they are pre-empted from bringing certain
7/2/15 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Controlled...
Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. In the Federal Register of August 27, 2014, FDA announced the availability of a draft guidance for ind
7/2/15 - Aurobindo Pharma: Resignation of Chief Executive Officer [Global Data Point]
With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R %7 ED for rapid filing of patents, Drug Master Files, Abbreviated New Drug Applications and formulation dossiers across the world.
7/2/15 - Federal Agencies Outline 21 Information Collection Options
WASHINGTON, July 2 The Federal Register issued the following information collection from federal agencies:. -National Oceanic and Atmospheric Administration: Evaluation Support Services. Since its establishment in 1970 under the Department of Commerce, the National Oceanic and Atmospheric Administration primary goals are to understand and predict
7/2/15 - Lupin Acquires Biocom in Russia
Pharma Major Lupin Limited today announced the acquisition of 100% equity stake in ZAO " Biocom" in Russia subject to certain closing conditions. Established in 1991, Biocom is a fast growing generic pharmaceutical company with a major focus on therapies such as cardiovascular, central nervous system and antimicrobials for systemic use and also doe
7/2/15 - Lupin Buys Russian Drug Company
NEW DELHI- Indian pharmaceuticals company Lupin Ltd on Thursday announced the acquisition of ZAO "Biocom" in Russia subject to certain closing conditions. Established in 1991, Biocom is a generic pharmaceutical company with focus on therapies such as cardiovascular, central nervous system and antimicrobials for systemic use and also does contract..
7/2/15 - The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals [Global Data Point]
The agreements follow MPP's June 9 announcement of sub-licences with Chinese firms, HEC Group and Huahai Pharmaceutical, for the generic production of Gilead Sciences' medicines.&# x0D;. "Over the past year, we have doubled the number of generic companies working with us to develop medicines for low- and middle-income countries," said Greg Perry,
7/2/15 - US Pharmaceutical Chemicals Market
US demand for pharmaceutical chemicals is forecast to rise 6.1 percent annually to $54 billion in 2019. Merchant market sales primarily to generic drug companies will account for nearly one-third of this total. The remainder of demand will consist of the value of pharmaceutical chemicals produced captively or con tracted for internal use by mak
7/2/15 - ViiV Healthcare & Desano Announce Manufacturing Agreement For Dolutegravir
LONDON- ViiV Healthcare and Desano Pharmaceuticals announced a strategic manufacturing agreement to enable production in China of dolutegravir. Based in Shanghai, Desano is a leading vertically integrated pharmaceuticals company specialising in developing and manufacturing of generic antiretroviral active pharmaceutical ingredient, or APIs, and...
7/1/15 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Licensing Provisions;...
All comments should be identified with the OMB control number 0910-0719. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. The Patient Protection and...
7/1/15 - Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Desvenlafaxine XR Tablets (Pristiq)
Breckenridge Pharmaceutical, Inc. announced today that Breckenridge and Alembic Pharmaceuticals Limited were granted final approval for their ANDA desvenlafaxine succinate extended-release tablets 50 mg and 100 mg, a generic version of Pristiq by Pfizer Inc. Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and..
7/1/15 - Corporate Reputation of Pharma in 2014 - a Perspective of Patient Groups with an Interest in Neurological Conditions - 2015 Edition
By a News Reporter-Staff News Editor at Biotech Week Research and Markets has announced the addition of the "Corporate Reputation of Pharma in 2014- a Perspective of Patient Groups with an Interest in Neurological Conditions- 2nd Edition" report to their offering. The increase is also due to the fact that the company rankings had slid previously
7/1/15 - DRL recalls two generic drugs in US [India Business] [Times of India]
HYDERABAD: City-headquartered pharma giant Dr Reddy's Laboratories has announced that it is voluntarily recalling two generic drugs, manufactured at its Bachupally facility, from the US market. According to the US Food and Drug Administration, Dr Reddy's Laboratories is recalling `Divalproex Sodium' extended-release tablets used for the treatment o
7/1/15 - Federal Agencies Outline 23 Information Collection Options
WASHINGTON, July 1 The Federal Register issued the following information collection from federal agencies:. -Census Bureau: Manufacturers' Unfilled Orders Survey. The Bureau of Economic Analysis, the Counsel of Economic Advisors, the Federal Reserve Board, the Conference Board, and members of the business community such as the National Associatio
7/1/15 - Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case
According to an Order issued in the U.S. District Court, Southern District of West Virginia on June 26th, the Court rejected the Plaintiff's assertion that one manufacturer can be held liable for injuries stemming from another manufacturer's product. Because of FDA regulations governing generic drug labels, they are pre-empted from bringing certain
7/1/15 - Marksans Pharma Acquires Time-Cap Lab
Deal Type: Acquisition Deal Sub Type: 100% Acquisition Deal Country: United States of America Deal Status: Completed Deal Value: 0.0000 USD. Marksans Pharma Ltd., a pharmaceutical company engaged in research, manufacturing and marketing of generic pharmaceutical formulation, through its wholly owned subsidiary Marksans Pharma Inc., has acquired 100
7/1/15 - RNCOS - Business Consultancy Services: Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
With a slew of major biologic blockbuster drugs up for patent expiry in the coming years, players involved in biosimilar production are leaving no stone unturned to cash in on the opportunity. A new research study conducted by RNCOS, "Global Biosimilar Market Outlook 2020", reveals that the market, which was worth US$ 1.89 Billion in 2014, is expec
7/1/15 - Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards
SCHAUMBURG, Ill., July 1, 2015/ PRNewswire-USNewswire/ The Coalition of State Rheumatology Organizations, a nationwide group of state and regional professional rheumatology societies, today released the findings of a national survey of rheumatologists that explored perceptions of biosimilars and the potential impact of these new drugs on patients
7/1/15 - Tennessee State Representative Sexton Honored as BIO State Legislator of the Year
By a News Reporter-Staff News Editor at Biotech Week The Biotechnology Industry Organization announced its selection of Tennessee State Representative Cameron Sexton as a state Legislator of the Year for 2015. Rep. Sexton, as Chairman of the Tennessee House Health Committee, sponsored and passed the Tennessee Affordable Drug Act, which authorized
7/1/15 - Teva Launches Generic Aggrenox Capsules in the United States
Teva Pharmaceutical Industries Ltd., today announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Teva recognizes the devastating impact of a stroke and is pleased to launch
7/1/15 - The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs)
Lupin, Strides, HEC Group, Huahai Bring Total Number of MPP Sub-licensees to Fourteen Companies. New companies Lupin and Strides Arcolab recently signed agreements to produce dolutegravir, a promising new HIV medicine the MPP licensed from ViiV Healthcare two months after its approval in Europe. The agreements follow MPP's June 9 announcement of...
7/1/15 - Unified prescription form is launched [The Daily Star, Beirut, Lebanon]
July 01 BEIRUT The unified prescription form, which makes it easier for Lebanese patients to access inexpensive medicine, was launched Tuesday in what Prime Minister Tammam Salam called a "great national achievement." According to Health Minister Wael Abu Faour, generic drugs comprise just 13 percent of the pharmaceutical market in Lebanon.
6/30/15 - Global Anti-Bacterial Drugs Market Assessment & Forecast 2015-2019
Dublin- Research and Markets has announced the addition of the "Global Anti-Bacterial Drugs Market Assessment& Forecast: 2015-2019" report to their offering. The majority can be attributed to large volume generic sales as well as a strongest innovative R&D activity in the sector with a large number of companies such as Cubist Pharmaceuticals, Cempr
6/30/15 - Hikma Pharma, Mallinckrodt Bid For Boehringer's Roxane Labs : Bloomberg
LONDON- Hikma Pharmaceuticals Plc. is among bidders for Boehringer Ingelheim GmbH's Roxane Labs business in the U.S., Bloomberg reported citing people familiar with the matter. The report said that other potential buyers for the generic pharmaceutical unit, which may fetch as much as 2 billion euros or $2.2 billion, include Mallinckrodt Plc and Per
Articles(s): 1 - 25 of 51     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415